Valuation: Jasper Therapeutics, Inc.

Market Cap 11.99M 10.48M 9.63M 8.98M 17.03M 1.14B 17.29M 116M 44.96M 561M 45.01M 44.04M 1.93B P/E 2026 *
-0.48x
P/E 2027 * -0.34x
Enterprise Value -270M -236M -217M -202M -384M -25.74B -390M -2.61B -1.01B -12.65B -1.01B -993M -43.61B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
98.81%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Jasper Therapeutics, Inc.

1 day-5.76%
1 week+25.60%
Current month+1.73%
1 month-13.07%
3 months-37.75%
6 months-76.60%
Current year-76.60%
1 week 0.36
Extreme 0.3645
0.48
1 month 0.32
Extreme 0.3151
0.6
Current year 0.32
Extreme 0.3151
2.07
1 year 0.32
Extreme 0.3151
4
3 years 0.32
Extreme 0.3151
31.01
5 years 0.32
Extreme 0.3151
188.8
10 years 0.32
Extreme 0.3151
188.8
Manager TitleAgeSince
Chief Executive Officer 54 2026-01-05
Director of Finance/CFO 54 2023-09-21
Chief Tech/Sci/R&D Officer 68 2023-03-22
Director TitleAgeSince
Director/Board Member 54 2026-01-05
Director/Board Member 70 2021-09-03
Director/Board Member 58 2021-09-23
Date Insider Type Main position Quantity % Market Cap.
02-05Free

Chief Executive Officer

500,000 1.7867%
01-01Free

Chief Executive Officer

90,000 0.3216%
01-01Free

Chief Financial Officer

90,000 0.3216%
Change 5-day change 1-year change 3-year change Capi.($)
-5.76%+25.60%-93.67%-96.78% 11.99M
0.00%+5.70%+78.19%+135.99% 59.1B
+2.32%+5.03%+75.26%+92.31% 55.19B
+3.86%+6.93%-11.32%-10.57% 24.67B
+4.30%+7.95%+14.11%+440.44% 24.19B
+0.64%+7.14%+50.90%-1.05% 19.69B
-0.36%+8.82%+42.97%-27.97% 17.56B
0.00%+20.78%+186.15%+347.42% 16.22B
+4.91%+20.18%+48.55% - 14.84B
+3.50%+1.97%+21.02%+193.33% 14.04B
Average +1.33%+7.38%+41.22%+119.24% 24.55B
Weighted average by Cap. +1.83%+6.47%+59.58%+135.96%

Financials

2026 *2027 *
Net sales - -
Net income -36.99M -32.34M -29.72M -27.7M -52.54M -3.52B -53.34M -357M -139M -1.73B -139M -136M -5.97B -64.38M -56.28M -51.72M -48.21M -91.44M -6.13B -92.82M -621M -241M -3.01B -242M -236M -10.38B
Net Debt -282M -247M -227M -211M -401M -26.89B -407M -2.72B -1.06B -13.22B -1.06B -1.04B -45.54B -555M -485M -446M -415M -788M -52.81B -800M -5.35B -2.08B -25.96B -2.08B -2.04B -89.45B
Logo Jasper Therapeutics, Inc.
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting mast cell-driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU), and Asthma. The Company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (c-Kit) receptor on mast and stem cells. Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the cell-surface receptor c-Kit, also known as CD117, thereby inhibiting signaling through the receptor. The SCF/c-Kit pathway is a survival signal for mast cells. It is also developing briquilimab as a one-time conditioning therapy for severe combined immunodeficiency (SCID) patients undergoing a second stem cell transplant for which it is conducting a Phase 1/2 clinical trial.
Employees
22
Date Price Change Volume
26-07-02 US$0.4283 -5.76% 221,974
26-07-01 US$0.4545 +7.96% 342,172
26-06-30 US$0.4210 +0.29% 266,512
26-06-29 US$0.4198 +23.11% 974,759
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
0.4283USD
Average target price
9.167USD
Spread / Average Target
+2,040.25%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. JSPR Stock